Abingworth | Activity | F4

Abingworth Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

3 investments· JUL 2026 – AUG 2026Show all

Investment

Redx closed a $36M Series A and strengthened its board.

Redx

Redx Abingworth

redxpharma.comAUG 28, 2026

AUG 28, 2026

Investment

AdvanCell closed a $315M oversubscribed Series D for targeted alpha therapies.

AdvanCell

AdvanCell Abingworth

advancell.com.auJUL 15, 2026

JUL 15, 2026

Investment

Allotera (formerly Wugen) closed $35M for off-the-shelf CAR-T therapies.

Allotera Therapeutics

Allotera Therapeutics Abingworth

businesswire.comJUL 8, 2026

JUL 8, 2026

Milestone

Vera Therapeutics received FDA accelerated approval for TRUTAKNA in primary IgA nephropathy.

Vera Therapeutics

Vera Therapeutics Abingworth

ir.veratx.comJUL 7, 2026

JUL 7, 2026

Exit

Portfolio company Myricx Bio to be acquired by Novartis.

Myricx Bio

Myricx Bio Abingworth

myricxbio.comJUL 6, 2026

JUL 6, 2026

Investment

cAMPfield launched with a $180M Series A for an oral IBD therapy.

cAMPfield

cAMPfield Abingworth

campfieldtx.comJUN 18, 2026

JUN 18, 2026

Investment

Cytospire closed an oversubscribed GBP 61M ($83M) Series A for gamma delta T cell engagers.

Cytospire Therapeutics

Cytospire Therapeutics Abingworth

cytospire.comMAY 5, 2026

MAY 5, 2026

Exit

Portfolio company Soleno Therapeutics to be acquired by Neurocrine.

Soleno Therapeutics

Soleno TherapeuticsAbingworth

neurocrine.gcs-web.comAPR 6, 2026

APR 6, 2026

Investment

Participated in R1 Therapeutics' oversubscribed $77.5M Series A for hyperphosphatemia in CKD.

R1 Therapeutics

R1 Therapeutics Abingworth

r1therapeutics.comMAR 17, 2026

MAR 17, 2026

Team Change

Announced a leadership transition and appointments, with Bali Muralidhar named head of Abingworth.

Abingworth leadership transition and appointments

Abingworth

abingworth.comJAN 5, 2026

JAN 5, 2026

Investment

Solve Therapeutics raised $120M for ADCs targeting solid tumors.

Solve Therapeutics

Solve Therapeutics Abingworth

solvetx.comNOV 17, 2025

NOV 17, 2025

Investment

Iambic raised over $100M in an oversubscribed round for AI-discovered therapeutics.

Iambic Therapeutics

Iambic Therapeutics Abingworth

iambic.aiNOV 10, 2025

NOV 10, 2025

Exit

Portfolio company Verona Pharma to be acquired by Merck.

Verona Pharma

Verona Pharma Abingworth

veronapharma.comJUL 9, 2025

JUL 9, 2025

Investment

Antares launched with $177M for precision cancer medicines.

Antares Therapeutics

Antares Therapeutics Abingworth

antaresrx.comJUN 10, 2025

JUN 10, 2025

Page 1 of 2